Reference
Chappell NP, et al. Is FDA-Approved Bevacizumab Cost-Effective When Included in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer? Journal of Oncology Practice : 31 May 2016. Available from: URL: http://dx.doi.org/10.1200/JOP.2015.010470
Rights and permissions
About this article
Cite this article
Bevacizumab cost effective in platinum-resistant ovarian cancer. PharmacoEcon Outcomes News 755, 12 (2016). https://doi.org/10.1007/s40274-016-3119-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3119-9